Cargando…

High energy, double pass helium plasma dermal resurfacing: A prospective, multicenter, single‐arm clinical study

BACKGROUND: A previous multi‐center clinical study of low energy (20% power), single‐pass helium plasma dermal resurfacing (HPDR) showed positive results but did not fully reveal the true potential of this novel technology. A second multi‐center clinical study, reported herein, was therefore underta...

Descripción completa

Detalles Bibliográficos
Autores principales: Holcomb, J. David, Doolabh, Vaishali, Lin, Michael, Zimmerman, Edward
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305223/
https://www.ncbi.nlm.nih.gov/pubmed/35170772
http://dx.doi.org/10.1002/lsm.23524
_version_ 1784752274050908160
author Holcomb, J. David
Doolabh, Vaishali
Lin, Michael
Zimmerman, Edward
author_facet Holcomb, J. David
Doolabh, Vaishali
Lin, Michael
Zimmerman, Edward
author_sort Holcomb, J. David
collection PubMed
description BACKGROUND: A previous multi‐center clinical study of low energy (20% power), single‐pass helium plasma dermal resurfacing (HPDR) showed positive results but did not fully reveal the true potential of this novel technology. A second multi‐center clinical study, reported herein, was therefore undertaken to evaluate efficacy and safety of high energy (40%), double pass HPDR for treatment of facial rhytids (ClinicalTrials.gov Identifier: NCT04185909). METHODS: Fifty‐five eligible subjects seeking improvement in facial rhytids were enrolled for study at one of four investigational sites. All subjects underwent full‐face HPDR treatment. The forehead, nose, cheeks, and peri‐oral treatment zones were treated at 40% power with two passes whereas the peri‐orbital and jawline/mandibular zones were treated at 20% power (up to 40% for jawline/mandibular zone) and one or two passes. Photographic images of the face were captured using the VISIA‐CR system. Three‐month posttreatment Fitzpatrick Wrinkle and Elastosis Scale (FWS) scores were compared to baseline scores as determined by blinded independent photographic reviewers (IPRs) and study investigators. RESULTS: Blinded IPRs and study investigators observed a ≥1‐point FWS improvement in 100% of subjects with mean change in IPR FWS from baseline to the 90‐day visit of −3.6 (±1.2). 96.4% of subjects indicated “improvement” in appearance at the 90‐day visit utilizing the modified Global Aesthetic Improvement Scale. Evaluation of VISIA‐CR data revealed statistically significant improvements in wrinkles, brown spots, and pore counts. Overall, 269 Adverse Events in 55 subjects were reported; most were mild‐moderate in severity (99.3%), anticipated (86.2%), and of relatively short duration with most having resolved within 30 days (60.6%) of treatment. CONCLUSION: Treatment of facial rhytids with high energy, double pass HPDR as detailed herein enables a marked improvement in FWS that parallels or surpasses competing technologies. VISIA‐CR analysis demonstrates additional improvements in skin quality with statistically significant quantitative improvements in brown spots and enlarged pores as well as wrinkles. Effective rhytid effacement combines with high subject satisfaction and few unanticipated adverse events for a reasonable benefit‐risk ratio.
format Online
Article
Text
id pubmed-9305223
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93052232022-07-28 High energy, double pass helium plasma dermal resurfacing: A prospective, multicenter, single‐arm clinical study Holcomb, J. David Doolabh, Vaishali Lin, Michael Zimmerman, Edward Lasers Surg Med Clinical Reports BACKGROUND: A previous multi‐center clinical study of low energy (20% power), single‐pass helium plasma dermal resurfacing (HPDR) showed positive results but did not fully reveal the true potential of this novel technology. A second multi‐center clinical study, reported herein, was therefore undertaken to evaluate efficacy and safety of high energy (40%), double pass HPDR for treatment of facial rhytids (ClinicalTrials.gov Identifier: NCT04185909). METHODS: Fifty‐five eligible subjects seeking improvement in facial rhytids were enrolled for study at one of four investigational sites. All subjects underwent full‐face HPDR treatment. The forehead, nose, cheeks, and peri‐oral treatment zones were treated at 40% power with two passes whereas the peri‐orbital and jawline/mandibular zones were treated at 20% power (up to 40% for jawline/mandibular zone) and one or two passes. Photographic images of the face were captured using the VISIA‐CR system. Three‐month posttreatment Fitzpatrick Wrinkle and Elastosis Scale (FWS) scores were compared to baseline scores as determined by blinded independent photographic reviewers (IPRs) and study investigators. RESULTS: Blinded IPRs and study investigators observed a ≥1‐point FWS improvement in 100% of subjects with mean change in IPR FWS from baseline to the 90‐day visit of −3.6 (±1.2). 96.4% of subjects indicated “improvement” in appearance at the 90‐day visit utilizing the modified Global Aesthetic Improvement Scale. Evaluation of VISIA‐CR data revealed statistically significant improvements in wrinkles, brown spots, and pore counts. Overall, 269 Adverse Events in 55 subjects were reported; most were mild‐moderate in severity (99.3%), anticipated (86.2%), and of relatively short duration with most having resolved within 30 days (60.6%) of treatment. CONCLUSION: Treatment of facial rhytids with high energy, double pass HPDR as detailed herein enables a marked improvement in FWS that parallels or surpasses competing technologies. VISIA‐CR analysis demonstrates additional improvements in skin quality with statistically significant quantitative improvements in brown spots and enlarged pores as well as wrinkles. Effective rhytid effacement combines with high subject satisfaction and few unanticipated adverse events for a reasonable benefit‐risk ratio. John Wiley and Sons Inc. 2022-02-16 2022-07 /pmc/articles/PMC9305223/ /pubmed/35170772 http://dx.doi.org/10.1002/lsm.23524 Text en © 2022 The Authors. Lasers in Surgery and Medicine published by Wiley Periodicals LLC https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Clinical Reports
Holcomb, J. David
Doolabh, Vaishali
Lin, Michael
Zimmerman, Edward
High energy, double pass helium plasma dermal resurfacing: A prospective, multicenter, single‐arm clinical study
title High energy, double pass helium plasma dermal resurfacing: A prospective, multicenter, single‐arm clinical study
title_full High energy, double pass helium plasma dermal resurfacing: A prospective, multicenter, single‐arm clinical study
title_fullStr High energy, double pass helium plasma dermal resurfacing: A prospective, multicenter, single‐arm clinical study
title_full_unstemmed High energy, double pass helium plasma dermal resurfacing: A prospective, multicenter, single‐arm clinical study
title_short High energy, double pass helium plasma dermal resurfacing: A prospective, multicenter, single‐arm clinical study
title_sort high energy, double pass helium plasma dermal resurfacing: a prospective, multicenter, single‐arm clinical study
topic Clinical Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305223/
https://www.ncbi.nlm.nih.gov/pubmed/35170772
http://dx.doi.org/10.1002/lsm.23524
work_keys_str_mv AT holcombjdavid highenergydoublepassheliumplasmadermalresurfacingaprospectivemulticentersinglearmclinicalstudy
AT doolabhvaishali highenergydoublepassheliumplasmadermalresurfacingaprospectivemulticentersinglearmclinicalstudy
AT linmichael highenergydoublepassheliumplasmadermalresurfacingaprospectivemulticentersinglearmclinicalstudy
AT zimmermanedward highenergydoublepassheliumplasmadermalresurfacingaprospectivemulticentersinglearmclinicalstudy